China’s Harbour BioMed has launched a new biotech to develop bispecific antibodies focused on the holy grail of next-gen ...
Harbour BioMed launches Élancé Therapeutics to advance next-generation obesity therapies: Cambridge, Massachusetts Thursday, March 13, 2025, 18:00 Hrs [IST] Harbour BioMed, a gl ...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company specializing in novel antibody therapeutics for immunology ...
Harbour BioMed, a global biopharmaceutical company committed to the discovery, development, and commercialization of novel ...
Vietnam Investment Review on MSN4d
Harbour BioMed Appoints Michael D. Patten as Chief Strategy OfficerHarbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Harbour BioMed (HKEX: 02142) has appointed Michael Patten as chief strategy officer, responsible for overseeing global ...
Harbour Biomed Ltd. has announced the launch of Élancé Therapeutics with an aim to improve the treatment of obesity. Élancé ...
Michael D. Patten as Chief Strategy Officer.
Patten will also serve as the Head of Global Alliance and lead efforts to manage and strengthen the company’s partner network ...
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 12, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback